MétaCan
Menu
Back to cohort
Record W2793567807 · doi:10.1093/ecco-jcc/jjx180.884

P757 Long-term effectiveness and safety of adalimumab based on Crohn’s disease duration: Results from the PYRAMID registry

2018· article· en· W2793567807 on OpenAlexaff
Edward V. Loftus, Walter Reinisch, Remo Panaccione, Sjoerd A.A. van den Berg, Mareike Bereswill, Jasmina Kalabic, Martha Skup, J Petersson, Anne Robinson, Geert D’Haens

Bibliographic record

VenueJournal of Crohn s and Colitis · 2018
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsUniversity of Calgary
Fundersnot available
KeywordsAdalimumabDuration (music)MedicineTerm (time)Pyramid (geometry)Crohn's diseaseDiseaseInternal medicineMathematicsPhysics

Abstract

fetched live from OpenAlex

PYRAMID was a non-interventional, uncontrolled, multinational registry of adult patients with Crohn’s disease (CD) assessing the long-term safety and effectiveness of adalimumab (ADA; Humira®) in clinical practice. In these analyses, the relationship between CD duration at registry enrolment (baseline [BL]) and treatment outcomes was evaluated in ADA-naïve patients at BL. Adults (≥(dults [BL]) amoderate-to-severe CD newly prescribed or already receiving ADA were followed for ≤6 years. Effectiveness was evaluated in ADA-naïve patients with ≥1 ADA dose and ≥1 post-enrolment measurement using the Harvey-Bradshaw Index (HBI), Short Inflammatory Bowel Disease Questionnaire (SIBDQ) and Work Productivity and Activity Impairment (WPAI) questionnaire. Data were summarised descriptively as observed; change from BL values was calculated for patients with available values at BL and yearly visits, irrespective of receiving ADA at assessment time, and stratified by BL CD duration (<2, 2 to <5, 5 to <10, and ≥10 years). Adverse events (AEs) were analysed in ADA-naïve patients by CD duration at BL; treatment-emergent AE rates (AEs occurring from BL through 70 days after last ADA dose in registry) were assessed as events per 100 patient-years (E/100 PYs) of registry ADA exposure. Of 5025 registry patients evaluated, 2057 (40.9%) were ADA-naïve at BL. BL CD duration was available for 1980 ADA-naïve patients (<2 years, n = 373; 2–<5 years, n = 334; 5–<10 years, n = 512; ≥10 years, n = 761). Mean total HBI and SIBDQ scores improved from BL in all subgroups at year 1 and these improvements were maintained, with numerically similar improvements across subgroups (Table 1). Mean WPAI subscores improved in all subgroups from BL to year 1 and remained mostly stable through year 6; numerically greater improvements were seen in patients with CD duration <5 vs. ≥5 years. Improvements in SIBDQ (all time points) and WPAI (nearly all time points) scores were clinically meaningful. Overall rates of any AE were generally similar across subgroups, as were rates of infection (7.4–9.0 E/100 PYs) and serious infection (4.4–6.4 E/100 PYs). Initiation of ADA treatment improved patient-reported quality of life and work-related activities in adults with CD. These improvements were maintained for up to 6 years across CD duration subgroups through registry participation. The safety profile for ADA-naïve patients was generally similar across subgroups and comparable with safety data previously reported for the overall registry population.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.007
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.028

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.007
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.007
GPT teacher head0.241
Teacher spread0.235 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Crohn s and ColitisSame topicInflammatory Bowel DiseaseFrench-language works237,207